



## Lebrikizumab


Catalogue No.: abx831187



SDS-PAGE analysis of Lebrikizumab.



Indirect ELISA analysis for the detection of Human IL13.



SEC-HPLC analysis of Lebrikizumab.

Lebrikizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL13, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Lebrikizumab has been used in trials studying the treatment of Asthma, Allergic Asthma, Atopic Dermatitis, Idiopathic Pulmonary Fibrosis, and COPD, Chronic Obstructive Pulmonary Disease.

<b>Target:</b>	IL13
<b>Clonality:</b>	Monoclonal
<b>Reactivity:</b>	Human
<b>Expression:</b>	Recombinant
<b>Tested Applications:</b>	ELISA, WB

# Datasheet

Version: 5.0.0

Revision date: 30 May 2025



**Host:** Human

**Recommended dilutions:** Optimal dilutions/concentrations should be determined by the end user.

**Conjugation:** Unconjugated

**Isotype:** IgG4 Kappa

**Form:** Liquid

**Purity:** > 95% (SDS-PAGE)

**Purification:** Purified from cell culture supernatants by Protein A/G chromatography.

**Storage:** Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

**Buffer:** 0.01 M PBS, pH 7.4.

**CAS Number:** 953400-68-5

**Concentration:** 1.28 mg/ml

**Note:** THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.